Cresswell et al [23] demonstrated absolute clinical equivalence and substantial savings for utilizing HCV-Ag in place of HCV-RNA for the diagnosis of acute hepatitis C. Additionally, for treatment monitoring, HCV-Ag allows savings because it is less expensive than RNA [14, 23], does not need specialized technicians and, most of all, has a much faster turnaround time that allows a result to be available in 1 hour compared to up to 7 hours for HCV-RNA [12, 14]. The gene discussed is RENBP; the disease is hepatitis C virus infection.